RMD Open

is an open access, peer-reviewed rheumatology journal from BMJ and EULAR, publishing original research on rheumatic and musculoskeletal disorders and connective tissue diseases

Impact Factor: 5.806
Citescore: 7.1
All metrics >>

RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation. Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

It is an online only open access journal that aims to provide rapid publication of research through a continuous publication model. All submitted content is subject to peer review prior to publication. Published work is free to read.

RMD Open is an official journal of EULAR.

Listen to the ARD and RMD Open podcast and subscribe in all podcast platforms, including Apple Podcasts, Google Podcasts, Stitcher and Spotify.

You can keep up with the latest news via Twitter and Facebook.

Editorial team

Current Issue

Latest Articles

Psoriatic arthritis:

Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry

25 May 2023

Sjo[x0308]gren syndrome:

Alteration of innate lymphoid cell homeostasis mainly concerns salivary glands in primary Sjögrens syndrome

25 May 2023

Education:

Educational readiness among health professionals in rheumatology: low awareness of EULAR offerings and unfamiliarity with the course content as major barriers--results of a EULAR-funded European survey

25 May 2023

Osteoarthritis:

Associations between markers of inflammation and altered pain perception mechanisms in people with knee osteoarthritis: a systematic review

24 May 2023

Rheumatoid arthritis:

Grip strength reduction in clinically suspect arthralgia: natural trajectories and improvement after treatment

23 May 2023

Video Abstract

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

20 February 2023

Conclusion: In the SENSCIS trial, subjects with SSc-ILD who had early SSc, elevated inflammatory markers or extensive skin fibrosis had a more rapid decline in FVC over 52 weeks than the overall trial population. Nintedanib had a numerically greater effect in patients with these risk factors for rapid ILD progression.

Find out more

EULAR Congress 2023

The 2023 EULAR Congress will be taking place on 31 May – 03 June in Milan, Italy as a hybrid event.

The aim of the European Congress of Rheumatology is to provide a forum of the highest standard for scientific (both clinical and basic), educational and social exchange between professionals involved in rheumatology, liaising with patient organisations, in order to achieve progress in the clinical care of people with rheumatic diseases.

View the Scientific Programme to plan your visit.

Visit the website for more information